Cenderitide
Designer natriuretic peptide. Not FDA-approved; investigational.
What it is
Cenderitide (also called CD-NP) is a designer chimeric peptide that combines portions of C-type natriuretic peptide (CNP) and dendroaspis natriuretic peptide (DNP, originally from green mamba snake venom). It was developed at the Mayo Clinic by John Burnett and colleagues as an investigational treatment for heart failure.
The chimeric design was intended to combine properties of multiple natriuretic peptides. Cenderitide has been studied in clinical trials but has not been approved. Cenderitide is not FDA-approved for any use in the United States.
Mechanism of action
Proposed mechanisms come from laboratory, animal, and early human research. Cenderitide was designed to activate both NPR-A and NPR-B receptors and has been reported to produce vasodilation, natriuresis, and anti-fibrotic effects in experimental models, similar to other natriuretic peptides.
Clinical evidence
Early-phase clinical trials in heart failure have been conducted and reported hemodynamic effects consistent with natriuretic peptide activity. Commercial development has been limited, and well-controlled trials establishing effectiveness and safety are lacking.
Why we don’t prescribe it at The Tide
The Tide does not prescribe or offer cenderitide. It is an investigational cardiovascular drug studied for heart failure.
Side effects and contraindications
Low blood pressure (hypotension) is the primary safety concern reported. Human safety has not been established, and long-term effects are unknown.